Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

This is the first systematic review of the safety of ketamine in the treatment of depression
after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and …

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP),
dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia …

Subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, impair
prefrontal cortex (PFC) function in the rat and produce symptoms in humans similar to those …

Recent advances in the understanding of brain cannabinoid receptor function have renewed
interest in the association between cannabinoid compounds and psychosis. In a 3-day …

Rationale: Since the mid-1970s, cross-species translational studies of prepulse inhibition
(PPI) have increased at an astounding pace as the value of this neurobiologically …

Administration of noncompetitive NMDA/glutamate receptor antagonists, such as
phencyclidine (PCP) and ketamine, to humans induces a broad range of schizophrenic-like …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …

Several decades of research attempting to explain schizophrenia in terms of the dopamine
hyperactivity hypothesis have produced disappointing results. A new hypothesis focusing on …